Replies to post #11969 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>I wonder if the nondisclosure [of detailed deal terms] is to prevent a sell-off or a run-up????<

Nothing that sinister, IMO. It’s quite common for biotech deals to have the detailed terms withheld from investors. According to Tom Newberry, it was Ovation who insisted on limiting disclosure.

Note that the level of disclosure in the Ovation deal is not that different from the level of disclosure in GTC’s deal with Leo.


Let’s talk biotech!
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”